Nightingale Health Oyj
F:7XE
Intrinsic Value
Nightingale Health Oyj engages in the development of health data platform for healthcare service providers. [ Read More ]
The intrinsic value of one
7XE
stock under the Base Case scenario is
0.52
EUR.
Compared to the current market price of 1.87 EUR,
Nightingale Health Oyj
is
Overvalued by 72%.
7XE's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
7XE or that its price is influenced by factors unrelated to fundamentals.
Nightingale Health Oyj's market capitalization is 112.8m EUR.
7XE stock price is 1.87 EUR.
7XE stock (0.52 EUR) is 72% less than its price (1.87 EUR).
7XE. Open DCF Valuation
7XE stock (0.52 EUR) is 72% less than its price (1.87 EUR). Open Relative Valuation
7XE has downside potential of 40% compared to the average analyst price target.
Open Wall St Estimates
7XE's Altman Z-Score is equal to 2.06.
7XE's Revenue has grown by an exceptional 81% over the past 12 months.
7XE's ROE (Return on Equity) for the past 12 months is negative and is equal to -17%.
7XE has negative Operating Income for the last twelve months.
7XE has negative Net Income for the last twelve months.
7XE's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -77%.
7XE's Revenue is forecast to grow at a rate of 54% per year over the next 3 years.
7XE has positive Gross Profit for the last twelve months.
7XE has negative Free Cash Flow for the last twelve months.
7XE has negative three-year average ROE (Return on Equity): -16%. The company is not efficient at transforming stockholders' equity into net income.
7XE's D/E (Debt to Equity) is very low and is equal to 0.03.
7XE has negative three-year average ROIC (Return on Invested Capital): -59%. The company is not efficient at using invested capital to generate operating income.
7XE's short-term assets (82m EUR) exceed its short-term liabilties (7m EUR).
7XE's long-term assets (107m EUR) exceed its long-term liabilties (9m EUR).
7XE has negative Net Debt. This means that the company has more cash and short-term investments (81m EUR) than debt (3m EUR).
7XE doesn't generate enough operating income (-18m EUR) to safely cover interest payments on its debt (202k EUR).
Valuation Backtest
Nightingale Health Oyj
Run backtest to discover the historical profit from buying and selling
7XE
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Nightingale Health Oyj
Balance Sheet Decomposition
Nightingale Health Oyj
| Current Assets | 82m |
| Cash & Short-Term Investments | 80.6m |
| Receivables | 824k |
| Other Current Assets | 549k |
| Non-Current Assets | 24.8m |
| Long-Term Investments | 69k |
| PP&E | 7.2m |
| Intangibles | 17.1m |
| Other Non-Current Assets | 431k |
| Current Liabilities | 6.8m |
| Accounts Payable | 3.4m |
| Other Current Liabilities | 3.4m |
| Non-Current Liabilities | 2.7m |
| Long-Term Debt | 2.7m |
| Other Non-Current Liabilities | -1k |
Earnings Waterfall
Nightingale Health Oyj
|
Revenue
|
4.2m
EUR
|
|
Cost of Revenue
|
-590k
EUR
|
|
Gross Profit
|
3.6m
EUR
|
|
Operating Expenses
|
-22.1m
EUR
|
|
Operating Income
|
-18.5m
EUR
|
|
Other Expenses
|
407k
EUR
|
|
Net Income
|
-18.1m
EUR
|
Free Cash Flow Analysis
Nightingale Health Oyj
7XE Profitability Score
Profitability Due Diligence
Nightingale Health Oyj's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Nightingale Health Oyj's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
7XE Solvency Score
Solvency Due Diligence
Nightingale Health Oyj's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Nightingale Health Oyj's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
7XE Price Targets Summary
Nightingale Health Oyj
According to Wall Street analysts, the average 1-year price target for
7XE
is 1.12 EUR
with a low forecast of 0.99 EUR and a high forecast of 1.28 EUR.
Shareholder Return
7XE Price
Nightingale Health Oyj
| Average Annual Return | -50.43% |
| Standard Deviation of Annual Returns | 30.38% |
| Max Drawdown | -88% |
| Market Capitalization | 112.8m EUR |
| Shares Outstanding | 62 240 998 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Nightingale Health Oyj
Country
Industry
Market Cap
Dividend Yield
Description
Nightingale Health Oyj engages in the development of health data platform for healthcare service providers. The company is headquartered in Helsinki, Etela-Suomen and currently employs 77 full-time employees. The company went IPO on 2021-03-19. The blood analysis technology developed by Nightingale measures a broad group of biomarkers from a single blood sample, recognizing individual disease risks. The firm provides people with comprehensive insights on health, helps them make better decisions regarding their health and connects them with healthcare experts that offer preventative services for maintaining health. Nightingale Health Oy is the Parent Company in the Nightingale Group. The Group comprises the parent Company’s subsidiaries: Nightingale Health United States Inc, Nightingale Health Asia Pte Ltd, Nightingale Health Japan KK as well as NG Health Sweden AB. The firm owns and independently oversees two laboratories in Finland, in Helsinki and Kuopio, and one laboratory in Tokyo, Japan.
Contact
IPO
Employees
Officers
The intrinsic value of one
7XE
stock under the Base Case scenario is
0.52
EUR.
Compared to the current market price of 1.87 EUR,
Nightingale Health Oyj
is
Overvalued by 72%.
You don't have any saved screeners yet
